Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy(66 views) Colombatto P, Palmisano E, Ricco G, Cavallone D, Oliveri F, Coco B, Salvati A, Romagnoli V, Surace L, Vatteroni M, Pistello M, Virdis A, Bonino F, Brunetto MR
J Clin Med (ISSN: 2077-0383electronic), 2022 Mar 04; 11
(5
): N/D-N/D.
Hepatology Unit, Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Centre of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, 56124 Pisa, Italy
riccogabriele@gmail.com (G.R.)
danielacavallone@hotmail.com (D.C.)
f.oliveri@ao-pisa.toscana.it (F.O.)
b.coco@ao-pisa.toscana.it (B.C.)
salvatiantonio@hotmail.com (A.S.)
v.romagnoli@ao-pisa.toscana.it (V.R.)
lidia.surace@gmail.com (L.S.)
Internal Medicine Unit, University of Pisa, 56126 Pisa, Italy
e.palmisano1@studenti.unipi.it (E.P.)
agostino.virdis@med.unipi.it (A.V.)
Virology Unit, University Hospital of Pisa, 56124 Pisa, Italy
l.vatteroni@ao-pisa.toscana.it (M.V.)
mauro.pistello@med.unipi.it (M.P.)
Institute of Biostructure and Bioimaging, National Research Council, 80145 Naples, Italy
ferruccio.bonino@unipi.it
References: Not available.
Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy
Direct-acting antivirals (DAAs) for hepatitis C virus (HCV) may induce hepatitis B virus (HBV) reactivations in co-infected patients, whose dynamics and outcomes could depend on the phase of HBV infection. We investigated HBsAg and HBV-DNA kinetics in fifteen untreated HBeAg Negative Infection (ENI) (4F-11M, 62.1y) and eight Nucleos(t)ide Analogs (NAs) treated Chronic Hepatitis B (CHB) (3F-6M, 54.8y) with HCV co-infection, receiving DAAs-regimens including Sofosbuvir (13) or not (10). All achieved a sustained virologic response (SVR) and normalized alanine-aminotransferase (ALT). At the direct acting antivirals’ (DAAs) baseline (BL), the HBV-DNA was undetectable (<6 IU/mL) in eight ENI and all CHB, the mean Log-HBsAg was lower in ENI than CHB (0.88 vs. 2.42, p = 0.035). During DAAs, HBV-DNA increased in untreated ENI by >1 Log in five and became detectable in two. Accordingly, mean BL Log-HBV-DNA (0.89) increased at week-4 (1.78; p = 0.100) and at the end of therapy (1.57; p = 0.104). Mean Log-HBsAg decreased at week-4 in ENI (from 0.88 to 0.55; p = 0.020) and CHB (from 2.42 to 2.15; p = 0.015). After DAAs, the HBsAg returned to pre-treatment levels in CHB, but not in ENI (six cleared HBsAg). Female gender and SOF were associated with a greater HBsAg decline. In conclusion, HBV reactivations during DAAs in HCV co-infected ENI caused moderate increases of HBV-DNA without ALT elevations. The concomitant HBsAg decline, although significant, did not modify individual pre-treatment profiles.
Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G * The relationship between cerebral vascular disease and parkinsonism: The VADO study(674 views) Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780. Impact Factor:3.274 ViewExport to BibTeXExport to EndNote